Data from Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor–Tyrosine Kinase Inhibitors

Abstract

<div>Abstract<p><b>Purpose:</b> Diarrhea occurs in approximately half of patients with metastatic renal cell carcinoma (mRCC) receiving vascular endothelial growth factor–tyrosine kinase inhibitors (VEGF-TKI). We evaluated the relationship between VEGF-TKI–related diarrhea and stool microbiota.</p><p><b>Experimental Design:</b> Stool samples were collected from 20 mRCC patients receiving VEGF-TKIs. 16S rRNA sequencing was used to characterize the stool bacteriomic profiling of patients. Assay validation with <i>Salmonella typhimurium</i> spike-in experiments suggested greatest speciation with use of the V5 region.</p><p><b>Results:</b> Higher levels of <i>Bacteroides</i> spp. and lower levels of <i>Prevotella</i> spp. were found in patients with diarrhea. In addition, patients receiving VEGF-TKIs with mRCC appeared to have less relative abundance of <i>Bifidobacterium</i> spp. as compared with previous reports based on healthy subjects.</p><p><b>Conclusions:</b> We have thus demonstrated interplay between microbiota and VEGF-TKI–induced diarrhea. Further studies are warranted to evaluate the potential causative role of preexisting dysbiosis in VEGF-TKI–related diarrhea. <i>Clin Cancer Res; 21(23); 5286–93. ©2015 AACR</i>.</p></div>